Ask most manufacturers of disposable medical consumables why a product carries a single-use label, and the honest answer is often "because it always has." The European Commission's proposed MDR rewrite is designed to make that answer insufficient.
The proposal was published in December 2025. By July 2026, Parliament had tabled nearly 800 amendments; the SANT committee is now seeking a compromise ahead of a vote expected in early 2027, with trilogues likely in the first half of 2027. Industry estimates for a final text range from mid-2027 to early 2028. The current MDR remains fully applicable in the meantime.
Most commentary has focused on software, certificates and clinical equivalence. For disposable consumables, the consequential change is Article 17.
From default label to documented conclusion
The Commission's proposed Article 17(1) sets a new test: a device may be intended for single use only where the manufacturer, in light of its design, construction, material, chemical, physical and biological properties, cannot ensure it will continue to meet safety and performance requirements when reused after appropriate reprocessing. The justification must form part of the Annex II technical documentation.
That is a subtle but important inversion. Today, single-use is the default assumption for anything that touches a patient. Under the proposed text, it becomes a conclusion supported by design and material characteristics. If the manufacturer cannot make that case, the device is not single-use — and must carry instructions for appropriate reprocessing.
The same article treats an organisation that fully refurbishes a single-use device as its manufacturer. The new rules would apply five years after entry into force, so the practical effect is still some distance away. The direction of travel is clear.
Why this is harder for consumables than for implants
For a hip implant, reuse is largely settled by clinical practice and physics. For a suction catheter or a feeding bag, the question is genuinely technical — and many technical files do not answer it in the language the new text requires.
A defensible rationale usually needs evidence in four areas:
- Material degradation. How do tensile strength, elasticity, hardness and plasticiser migration change after repeated cleaning and sterilisation? PVC, silicone, polypropylene and polyethylene behave differently; "medical-grade" is no substitute for cycle data.
- Cleanability by design. Long narrow lumens, dead spaces and multi-part connectors are hard to validate as cleanable. Address geometry, not just intended use.
- Biological risk. Biofilm, residual protein and cross-contamination belong in the file as assessed risks — not as a line in the brochure.
- Function after reprocessing. Seal integrity, connector fit, dose accuracy, label legibility and packaging performance all matter if reuse is to be ruled out on technical grounds.
None of this is exotic. Most of it sits in design verification, biocompatibility and sterilisation validation reports manufacturers already hold. The gap is synthesis: the data exist, but no one has written the argument that connects them to the single-use claim.
The procurement consequence
Hospitals face simultaneous pressure to cut costs and reduce single-use plastics. A regulator-backed justification gives procurement teams a clear basis to challenge suppliers — and gives reprocessing companies a clear target. Where hospital reprocessing is established, a thin rationale invites the account to move.
The reverse is also true. A supplier that can explain, in two pages and with data, why a device cannot be safely reprocessed has a stronger tender position than one that repeats "for single-use only." That explanation is auditable because it lives in the technical file, not a sales deck.
What else changes — and what does not
The revision is broader than Article 17. The Commission also proposes removing the five-year cap on notified body certificates, scaling notified body involvement to device risk, letting some lower-risk software self-certify, relaxing the contractual requirement for clinical equivalence, and creating fast-track pathways for orphan and breakthrough devices. Parliament broadly supports risk-based assessment but remains divided on single-use and equivalence for higher-risk devices.
For procurement, the practical message is patience. Certificate rules may change, but not yet; surveillance audit status and scope changes already matter more than the expiry date on a PDF. And the core of the system — safety and performance requirements, ISO 13485, clinical evaluation, post-market surveillance, vigilance and UDI/EUDAMED — is not going away. Emergo by UL's advice is blunt and correct: keep working toward the current MDR, because the content and timing of future changes cannot be guaranteed.
What to do in the next two quarters
- Audit the top 20 SKUs by revenue. Does each technical file contain a specific reuse-resistance rationale? A paragraph about infection control is not enough.
- Check existing evidence. Sterilisation cycle data, aging studies and cleanability assessments can usually be reused; commission missing testing now, while timelines are under your control.
- Write one approved paragraph for tenders — and do not change labels or IFUs yet. Regulatory affairs and sales should agree on language that explains the designation without overclaiming, while the SANT vote and trilogue play out.
The bottom line
Simplification is not uniform. For some manufacturers, the revision removes paperwork. For makers of disposable consumables, it adds a burden of proof: the single-use claim must be earned with design and material evidence, not inherited from habit. Suppliers who can show — with data, not adjectives — why their products cannot be safely reused will be better placed in the next tender cycle. Those who treat "single-use" as a label rather than a conclusion will find it uncomfortable.
WeHere Medical has manufactured disposable medical consumables for more than 25 years, operating three owned factories and a network of 45 audited partner factories, with ISO 13485-certified quality management and technical documentation aligned to EU MDR requirements. Our portfolio covers more than 2,500 products supplied to over 50 countries. Our regulatory and engineering teams work from the technical file outward — because that is where claims like "single-use" are actually defended. For specifications or a quote, we respond within 24 hours.
Sources
- Sidley Austin LLP, "A More Competitive MedTech Landscape in the EU? What the MDR/IVDR Revision Could Mean for MedTech Manufacturers and Investors," 16 October 2026.
- Emergo by UL, "Europe Targets Revised MDR and IVDR Adoption in Q2–Q3 2027," 9 October 2026.
- Association of Medical Device Reprocessors, "Major Reforms to EU Medical Device Regulations," 9 July 2026.
- European Commission, proposal for a targeted revision of Regulation (EU) 2017/745 and Regulation (EU) 2017/746, December 2025.
